BioTuesdays

Category - News

Autolus Logo

HCW starts Autolus Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Autolus Therapeutics (NASDAQ:AUTL) with a “buy” rating and $45 price target. The stock closed at $30.64 on Oct. 23. Autolus is a UK-based, oncology-focused, autologous cell therapy...

Gritstone Oncology

BTIG starts Gritstone Oncology at buy; PT $26

BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...

IntelGenx Logo

IntelGenx completes $12-million equity offering

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT)completed an offering of 17,144,314 units at a price of 70 (U.S.) cents each for gross proceeds of approximately $12-million. Each unit consists of one common share of...

Ra Medical

Piper Jaffray starts Ra Medical at OW; PT $23

Piper Jaffray initiated coverage of Ra Medical Systems (NASDAQ:RMED) with an “overweight” rating and price target of $23. The stock closed at $13.25 on Oct. 19. Ra makes and sells excimer laser products. While it has a...

Titan Pharmaceuticals Logo

Titan Pharma shares jump 33% on initiation by A.G.P.

Shares of Titan Pharmaceuticals (NASDAQ:TTNP) jumped 33% to close at 32 cents on Oct. 18 after A.G.P./Alliance Global Partners initiated coverage of Titan with a “buy” rating and price target of 45 cents. Turnover was a...

Y-mAbs Therapeutics Logo

BTIG starts Y-mAbs Therapeutics at buy; PT $35

BTIG launched coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and $35 price target. The stock closed at $21.60 on Oct. 15. Y-mAbs is in pivotal trials for the treatment of both primary neuroblastomas...